The treatment of cancer patients with immune checkpoint inhibitors (such as anti-CTLA-4, anti-PD-1, anti-PD-L1, or combinations of anti-PD-1/PD-L1 with anti-CTLA-4) has marked a major breakthrough in oncology in recent years. This evidence concerns the gene CTLA4 and cancer.